^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Iqirvo (elafibranor)

    i
    Other names: GFT505, GFT 505, GFT-505, IPN60190
    Associations

    News

    Trials
    Company:
    Genfit, Ipsen
    Drug class:
    PPAR α agonist, PPAR δ agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    ELMWOOD: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Ipsen | Trial completion date: Aug 2026 --> Sep 2031 | Trial primary completion date: Aug 2026 --> Sep 2031
    Trial completion date • Trial primary completion date
    |
    Iqirvo (elafibranor)
    10d
    Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy (clinicaltrials.gov)
    P=N/A, N=3, Not yet recruiting, Ipsen | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    |
    Iqirvo (elafibranor)
    1m
    ELASCOPE: A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (clinicaltrials.gov)
    P3, N=350, Recruiting, Ipsen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iqirvo (elafibranor)
    1m
    Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy (clinicaltrials.gov)
    P=N/A, N=3, Not yet recruiting, Ipsen
    New trial
    |
    Iqirvo (elafibranor)
    2ms
    ELFIDENCE: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=276, Recruiting, Ipsen | N=132 --> 276
    Enrollment change
    |
    Iqirvo (elafibranor)
    4ms
    ELASCOPE: A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (clinicaltrials.gov)
    P3, N=350, Not yet recruiting, Ipsen
    New P3 trial
    |
    Iqirvo (elafibranor)
    4ms
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial primary completion date
    |
    Iqirvo (elafibranor)
    6ms
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=69, Active, not recruiting, Ipsen | Trial completion date: Oct 2026 --> Jun 2026 | Trial primary completion date: Oct 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Iqirvo (elafibranor)
    1year
    Compound 3d Attenuates Metabolic Dysfunction-Associated Steatohepatitis via Peroxisome Proliferator-Activated Receptor Pathway Activation and Inhibition of Inflammatory and Apoptotic Signaling. (PubMed, Metabolites)
    This study aimed to evaluate the therapeutic potential of compound 3d, a novel elafibranor derivative, focusing on its dual mechanisms of PPAR pathway activation and p38 MAPK signaling inhibition... Compound 3d alleviates MASH via PPAR-mediated lipid metabolism enhancement and p38 MAPK-driven inflammation/apoptosis suppression, with additional gut microbiota modulation. These findings highlight 3d as a multi-target therapeutic candidate for MASH.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ACOX1 (Acyl-CoA Oxidase 1)
    |
    Iqirvo (elafibranor)
    1year
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=69, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Iqirvo (elafibranor)
    1year
    Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. (PubMed, World J Biol Chem)
    Future research should focus on elucidating EFN's molecular mechanisms and advancing its clinical application to establish its therapeutic potential in human populations. EFN represents a novel, comprehensive strategy for ALD management, targeting both liver and gut pathologies.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Iqirvo (elafibranor)
    over1year
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Recruiting, Ipsen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iqirvo (elafibranor)